Tango Therapeutics reported data that it judged sufficient to advance its pancreatic cancer candidate into a Phase 3 program and concurrently raised $225 million to fund development. The company said the midstage results met predefined thresholds and justified scaling the program toward registration. The financing will support the Phase 3 trial and broader pipeline priorities. Tango emphasized the need for accelerated development in pancreatic cancer, where clinical options remain limited, and signaled plans to engage potential partners and expand enrollment across specialized cancer centers.